Advancing Immune therapies

---

Vaxerna is a clinical stage peptide & mRNA immunotherapy vaccine company that is changing the treatment paradigm for life-threatening diseases of the immune system. Vaxernabuilds on 20+ years of pioneering chronic inflammatory disease research .

Vaxerna’s proprietary platform modifies immune responses, altering the course of autoimmune and allergic diseases and related asthma, rather than symptom suppression

Technology is innovative, safe, disruptive and strongly supported by regulators, changing the treatment paradigm for the life-threatening diseases it addresses

Vaxerna has world leading experience in the selection and delivery of peptides for the induction of tolerance. Moving forward, where feasible, we will deliver peptides using ground breaking RNA technology

Peptides offer overwhelming advantages in the induction of tolerance and their expression through RNA encoding those peptides combines two proven and synergistic technologies 

Substantial market opportunities exist to address significant unmet medical needs in autoimmune and allergic diseases. Vaxernawill disrupt the existing markets by offering disease altering remedies not symptomatic treatments 

Vaxerna has IP which dominates the application of peptides and polynucleotides expressing peptides in its target disease areas